Percheron Therapeutics Limited (AWY0)

Overview

Percheron Therapeutics Limited is a pioneering force in the biotechnology realm, focusing on the discovery and development of innovative antisense pharmaceuticals. Situated in Melbourne, Australia, and established back in 2000, the company has witnessed a notable evolution, transitioning from Antisense Therapeutics Limited to its current identity in December 2023. Percheron Therapeutics is at the forefront of addressing some of the most challenging diseases through its cutting-edge research, primarily concentrating on inflammatory conditions and diseases linked to excessive growth hormone action.

Products and Services

• ATL1102

  ATL1102 stands as a cornerstone in Percheron Therapeutics’ product pipeline, acting as an antisense inhibitor targeting CD49d. It is currently in Phase IIa clinical trials, demonstrating promise for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, asthma, and various other inflammatory disorders. By focusing on CD49d, ATL1102 aims to mitigate inflammation and immune responses that contribute to the pathology of these diseases.

• Atesidorsen (ATL1103)

  Atesidorsen, also recognized as ATL1103, is an oligonucleotide devised to suppress the growth hormone receptor, thereby aiming to decrease insulin-like growth factor-I levels in the bloodstream. This innovative approach targets conditions characterized by excessive growth hormone activity. Having completed Phase II clinical trials, Atesidorsen showcases Percheron’s commitment to addressing diseases associated with abnormal growth hormone levels, highlighting the company’s expertise in developing treatments that go beyond traditional therapeutic modalities.